BioTelemetry CE Mark for Holter analysis software

BioTelemetry (NSDQ:BEAT) said on Monday it won CE Mark approval in the European Union for its Holter analysis software.

The Pennsylvania-based company said the device is usable on a stand-alone basis or with any of its digital holter recorders, and that it expects to market the software under its Millenia brand name.

“With the achievement of this important milestone, we are excited to be one of the only international providers with a complete monitoring solution, offering both devices and software.  We believe that the global market offers the Company compelling growth possibilities, and we continue to invest in the expansion of our international operations.  While the software currently operates with our legacy Holter recorders, we expect to launch an integrated solution with our newly acquired ePatch device in the near future,” CEO Joseph Capper said in a press release.

BioTelemetry sells products including mobile cardiac telemetry, as well as event, continuous rhythm, digital Holter and INR self-monitoring.

In July, Both BioTelemetry and digital health startup InfoBionic celebrated a victory in an ongoing patent fight with each other over wireless cardiac monitoring technology.

BioTelemetry disclosed that the Massachusetts District Court stopped InfoBionic from making, using, marketing or selling in the U.S., or importing into the country, any of its first-generation MoMe Kardia system products.

Separately, however, Lowell-Mass.-based InfoBionic touted the court action as successfully resolving “obsolete patent claims.” The company also noted that as part of the agreement, it incurred no damages and “no monies were due” to BioTelemetry.

In May, BioTelemetry closed its $15.5 million acquisition of clinical trial imaging provider VirtualScopics (NSDQ:VSCP).

The post BioTelemetry CE Mark for Holter analysis software appeared first on MassDevice.

from MassDevice http://ift.tt/2bH11aC